{
    "nctId": "NCT01941771",
    "briefTitle": "Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer",
    "officialTitle": "Randomized Phase II Trial of Capecitabine Plus Oral Vinorelbine Day 1 and 8 vs Metronomic Capecitabine Plus Oral Vinorelbine as Treatment of Metastatic Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 110,
    "primaryOutcomeMeasure": "Primary endpoint is overall response rate i both arms.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Locally advanced or metastatic Human Epidermal Growth Factor Receptor2-Negative breast cancer\n* WHO performance status \\< 3\n\nExclusion Criteria:\n\n* Former treatment with Capecitabine or Vinorelbine\n* Patients who have received more than one line of chemotherapy for metastatic disease\n* Brain metastases\n* Malabsorption syndrome\n* Abnormal organ function\n* pregnant or lactating women",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}